MetaCap

Black Hawk Acquisition (BKHA) vs TScan Therapeutics (TCRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TScan Therapeutics is the larger company by market cap ($9.9 million vs $7.7 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BKHA-85.77%TCRX-47.31%
+4%-43%-90%
Oct 7, 20261 yearNov 20, 2026
BKHA-83.95%TCRX-38.70%
+4%-42%-88%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BKHA versus TCRX key metrics
MetricBKHATCRX
Share price$1.85$0.1459
Market cap$7.68M$9.89M
1-day change-71.45%+2.24%
YTD return—-85.41%
1-year return—-84.85%
5-year return—-98.33%
P/E ratio (TTM)5.61—
EPS (TTM)$0.33$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.32M
Revenue growth (YoY)—+266.65%
Net income (latest FY)$1.33M$-129.77M
Operating margin—-1315.38%
Net margin—-1256.81%
52-week high$23.00$1.47
52-week low$1.75$0.14
Distance from 52-week high-91.96%-90.07%
Analyst consensus—hold
Avg. price target upside—+585.40%
Average volume101.40K766.11K
Shares outstanding4.15M63.50M
Employees—138
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Black Hawk Acquisition

BKHA stock →

Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About TScan Therapeutics

TCRX stock →

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees

BKHA vs TCRX FAQ

Which is bigger, Black Hawk Acquisition or TScan Therapeutics?

TScan Therapeutics (TCRX) is larger, with a market capitalization of $9.89M compared with $7.68M for Black Hawk Acquisition (BKHA).

Are Black Hawk Acquisition and TScan Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons